Prime Medicine will trade on hype and fumes until it shows positive clinical data, likely not before sometime in 2027, because it is still a Phase 1 company. Its technology reads as almost too good to be true, but genomics has many promising players and it is hard to know now who will win, which favors a broad genomics ETF over a single name. x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

Prime Medicine looks unusually inexpensive relative to its platform at a roughly $570 million market cap. Bristol Myers Squibb's deal includes over $3.5 billion of potential milestones, six times that value, plus royalties, and gives Prime a route into cancer and immunology; their value depends on success, timing and costs. Prime editing can make all 12 single-letter DNA substitutions and insert or delete DNA, and its first CGD patients reached 69% and 83% functional neutrophils by day 30. x.com 

Super Micro Computer's $7 billion equity raise is heavy dilution to fund AI spending, and the market is never going to like a raise that large. The stock sold off on the news, fitting a broader weakness theme around dilution for AI spend. x.com  x.com  x.com 

Rubrik belongs in the too-hard pile until it proves it can make money and stop diluting shareholders. @InvestingVisual notes that net losses, dilution and stock compensation as a share of revenue are shrinking each quarter, but trending in the right direction is not good enough for a large investment; continued proof over time could prompt a rethink. x.com  x.com 

Prime Medicine's stock should start to move once more pipeline data comes in, building on amazing technology and early results in a rare immune disease showing quick fixes. More programs are coming, and its cash runway lasts until 2027. x.com 

IREN's governance is a red flag: it put a FinX influencer, Mike Alfred, on its board to shill the stock while continuously diluting shareholders through ATM offerings. It also acquired a PR company. Per @aleabitoreddit, IREN faces endless dilution like BKKT, ASST and SLNH, and Alfred has promoted every one of them. There is never a good reason to put an influencer on a board other than to have the stock promoted. x.com  x.com  x.com  x.com